In the first head-to-head comparison of two devices intended to protect against stroke in patients undergoing transcatheter aortic valve replacement (TAVR), the investigational Emboliner device ...
A device designed to capture more TAVR procedural debris proves noninferior to an existing device in a large trial, but the ...
The question remains: what will it take to prove that any protection device is having a meaningful impact on stroke risk?
Emboline's Emboliner system excels in a global trial, showing superior debris capture and procedural success in TAVR patients ...
PROTECT H2H is the first randomized IDE trial of an embolic protection device in TAVR to meet all primary and secondary safety and efficacy endpoints, representing a significant clinical and regulator ...
VANCOUVER, BRITISH COLUMBIA, CANADA, March 16, 2026 /EINPresswire.com/ — The global cardiac surgery device market is projected to grow from $21.1 billion in 2025 to ...
Add Yahoo as a preferred source to see more of our stories on Google. NOWDiagnostics' test has been proven in a clinical study of 1 JenaValve’s Trilogy transcatheter aortic valve replacement device ...
Medtronic (NYSE:MDT) today announced data from the ALERT trial aimed at addressing health disparities in structural heart care.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results